- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Guselkumab – July 2025
Guselkumab; Solution for I.V. infusion 200 mg in 20 mL vial, Injection 100 mg in 1 mL single use pre-filled pen, Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg in 1 mL single use pre-filled syringe, Injection 200 mg in 2 mL single use pre-filled syringe; Tremfya®
Last updated
9 July 2025
